# PPM1D

## Overview
PPM1D is a gene that encodes the protein phosphatase, Mg2+/Mn2+ dependent 1D, commonly referred to as Wip1. This protein is a serine/threonine phosphatase that plays a pivotal role in cellular processes, particularly in the regulation of the cell cycle and the DNA damage response. PPM1D is involved in dephosphorylating key proteins such as Chk1 and p53, which are integral to the ATM/ATR-mediated DNA damage response pathways, thereby facilitating the return of cells to a homeostatic state post-repair (Lu2005PPM1D). The protein's activity is crucial for modulating cell cycle checkpoints and maintaining genomic stability. Mutations and overexpression of PPM1D have been implicated in various cancers and intellectual disabilities, highlighting its clinical significance (Kamada2020Metaldependent; Jansen2017De). As a negative regulator of the DNA damage response, PPM1D's interactions with proteins such as p53 and Chk1 underscore its potential oncogenic effects when dysregulated (Douarre2013DNA; Lu2005PPM1D).

## Structure
The PPM1D protein, also known as Wip1, is a serine/threonine phosphatase with a unique molecular structure characterized by specific domains and loops. Its primary structure includes a sequence of amino acids forming the protein chain, with notable regions such as the Pro-rich loop (P-loop) and the basic amino acid residue-rich loop (B-loop) (Chuman2008Characterization; Kamada2020Metaldependent). The secondary structure of PPM1D features two antiparallel β-sheets forming a β-sandwich core, flanked by α-helices (Miller2022Allosteric).

The tertiary structure of PPM1D includes a catalytic domain essential for its phosphatase activity, with two metal-binding sites coordinated by acidic residues (Miller2022Allosteric). The protein also contains unique regions such as the flap (residues 219-295) and hinge (residues 155-166) regions, which are crucial for its conformational dynamics and interaction with inhibitors (Miller2022Allosteric). The flap region is involved in substrate recognition and can adopt different conformations, contributing to the protein's dynamic nature (Meller2023Discovery).

PPM1D has a splice variant known as PPM1D430, which is expressed in specific tissues like leukocytes and testis, differing from the ubiquitously expressed full-length PPM1D (Kamada2020Metaldependent). This variant has a distinct C-terminal sequence, which may affect its function and localization.

## Function
PPM1D, also known as Wip1, is a serine/threonine phosphatase that plays a crucial role in cell cycle regulation and the DNA damage response in healthy human cells. It is involved in dephosphorylating key proteins such as Chk1 and p53, which are integral to the ATM/ATR-mediated DNA damage response pathways. This dephosphorylation activity is essential for reversing the activation of these pathways once DNA damage has been repaired, thereby helping to return the cell to a homeostatic state (Lu2005PPM1D).

PPM1D is active in the nucleus and is known to modulate the cell cycle by ensuring that checkpoints are properly regulated, preventing unnecessary cell cycle arrest. It specifically dephosphorylates Chk1 at Ser 345, inhibiting its kinase activity and affecting downstream targets such as CDC25C, which influences the G2/M checkpoint (Lu2005PPM1D). PPM1D also plays a role in the regulation of the p38 MAPK pathway, which is activated by genotoxic stresses and is associated with p53-mediated transcription and apoptosis. By dephosphorylating p38, PPM1D down-regulates p53 activity, facilitating cellular homeostasis (Lu2005PPM1D).

## Clinical Significance
Mutations and alterations in the PPM1D gene are associated with various diseases, particularly cancers and intellectual disabilities. In cancer, PPM1D overexpression is linked to poor prognosis in several types, including breast, ovarian, colorectal, and esophageal squamous cell carcinoma (ESCC) (Kamada2020Metaldependent; Deng2020The). PPM1D mutations, especially truncating mutations, lead to increased protein stability and are implicated in chemotherapy resistance in hematopoietic cells and solid tumors like gliomas (Kahn2018PPM1Dtruncating; Khadka2022PPM1D). These mutations often result in a gain-of-function phenotype, contributing to tumor progression and drug resistance (Burocziova2023Ppm1d).

In the context of intellectual disabilities, de novo truncating mutations in PPM1D are linked to a syndrome characterized by mild to severe intellectual disability, developmental delay, and various behavioral problems (Jansen2017De). These mutations escape nonsense-mediated mRNA decay, leading to a stable truncated transcript that affects the stress-response pathway, although they do not significantly alter p53 signaling (Jansen2017De). Despite these mutations, there is no reported increase in cancer risk for individuals with germline PPM1D mutations associated with intellectual disability (Jansen2017De).

## Interactions
PPM1D, also known as Wip1, is a serine/threonine phosphatase that interacts with several key proteins involved in the DNA damage response and cell cycle regulation. It dephosphorylates and inactivates p53, a crucial tumor suppressor protein, thereby reducing its stability and activity in response to DNA damage (Douarre2013DNA; Lu2005PPM1D). PPM1D also interacts with Chk1, a checkpoint kinase, by dephosphorylating it at specific sites such as Ser317 and Ser345, which inhibits Chk1's kinase activity and affects cell cycle checkpoints (Douarre2013DNA; Lu2005PPM1D).

In addition to p53 and Chk1, PPM1D dephosphorylates other proteins involved in the DNA damage response, including g-H2AX, a marker of DNA double-strand breaks, and ATM/ATR, which are sensor kinases that activate DNA repair pathways (Douarre2013DNA; Lu2005PPM1D). These interactions allow PPM1D to modulate the DNA damage response by reducing cell cycle checkpoint activities and promoting the resolution of DNA damage foci (Douarre2013DNA).

PPM1D's interactions with these proteins highlight its role as a negative regulator of the DNA damage response, contributing to its potential oncogenic effects when overexpressed or mutated (Lu2005PPM1D).


## References


[1. (Kahn2018PPM1Dtruncating) Josephine D. Kahn, Peter G. Miller, Alexander J. Silver, Rob S. Sellar, Shruti Bhatt, Christopher Gibson, Marie McConkey, Dylan Adams, Brenton Mar, Philipp Mertins, Shaunt Fereshetian, Karsten Krug, Haoling Zhu, Anthony Letai, Steven A. Carr, John Doench, Siddhartha Jaiswal, and Benjamin L. Ebert. Ppm1d-truncating mutations confer resistance to chemotherapy and sensitivity to ppm1d inhibition in hematopoietic cells. Blood, 132(11):1095–1105, September 2018. URL: http://dx.doi.org/10.1182/blood-2018-05-850339, doi:10.1182/blood-2018-05-850339. This article has 163 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2018-05-850339)

[2. (Khadka2022PPM1D) Prasidda Khadka, Zachary J. Reitman, Sophie Lu, Graham Buchan, Gabrielle Gionet, Frank Dubois, Diana M. Carvalho, Juliann Shih, Shu Zhang, Noah F. Greenwald, Travis Zack, Ofer Shapira, Kristine Pelton, Rachel Hartley, Heather Bear, Yohanna Georgis, Spandana Jarmale, Randy Melanson, Kevin Bonanno, Kathleen Schoolcraft, Peter G. Miller, Alexandra L. Condurat, Elizabeth M. Gonzalez, Kenin Qian, Eric Morin, Jaldeep Langhnoja, Leslie E. Lupien, Veronica Rendo, Jeromy Digiacomo, Dayle Wang, Kevin Zhou, Rushil Kumbhani, Maria E. Guerra Garcia, Claire E. Sinai, Sarah Becker, Rachel Schneider, Jayne Vogelzang, Karsten Krug, Amy Goodale, Tanaz Abid, Zohra Kalani, Federica Piccioni, Rameen Beroukhim, Nicole S. Persky, David E. Root, Angel M. Carcaboso, Benjamin L. Ebert, Christine Fuller, Ozgun Babur, Mark W. Kieran, Chris Jones, Hasmik Keshishian, Keith L. Ligon, Steven A. Carr, Timothy N. Phoenix, and Pratiti Bandopadhayay. Ppm1d mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nature Communications, February 2022. URL: http://dx.doi.org/10.1038/s41467-022-28198-8, doi:10.1038/s41467-022-28198-8. This article has 32 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-022-28198-8)

[3. (Miller2022Allosteric) Peter G. Miller, Murugappan Sathappa, Jamie A. Moroco, Wei Jiang, Yue Qian, Sumaiya Iqbal, Qi Guo, Andrew O. Giacomelli, Subrata Shaw, Camille Vernier, Besnik Bajrami, Xiaoping Yang, Cerise Raffier, Adam S. Sperling, Christopher J. Gibson, Josephine Kahn, Cyrus Jin, Matthew Ranaghan, Alisha Caliman, Merissa Brousseau, Eric S. Fischer, Robert Lintner, Federica Piccioni, Arthur J. Campbell, David E. Root, Colin W. Garvie, and Benjamin L. Ebert. Allosteric inhibition of ppm1d serine/threonine phosphatase via an altered conformational state. Nature Communications, June 2022. URL: http://dx.doi.org/10.1038/s41467-022-30463-9, doi:10.1038/s41467-022-30463-9. This article has 22 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-022-30463-9)

[4. (Meller2023Discovery) Artur Meller, Saulo De Oliveira, Aram Davtyan, Tigran Abramyan, Gregory R. Bowman, and Henry van den Bedem. Discovery of a cryptic pocket in the ai-predicted structure of ppm1d phosphatase explains the binding site and potency of its allosteric inhibitors. Frontiers in Molecular Biosciences, April 2023. URL: http://dx.doi.org/10.3389/fmolb.2023.1171143, doi:10.3389/fmolb.2023.1171143. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2023.1171143)

[5. (Chuman2008Characterization) Yoshiro Chuman, Hiroaki Yagi, Tomohiko Fukuda, Takao Nomura, Miho Matsukizono, Yasuyuki Shimohigashi, and Kazuyasu Sakaguchi. Characterization of the active site and a unique uncompetitive inhibitor of the ppm1-type protein phosphatase ppm1d. Protein &amp; Peptide Letters, 15(9):938–948, September 2008. URL: http://dx.doi.org/10.2174/092986608785849236, doi:10.2174/092986608785849236. This article has 22 citations.](https://doi.org/10.2174/092986608785849236)

[6. (Deng2020The) Wenhong Deng, Jieqing Li, Kimberly Dorrah, Denise Jimenez-Tapia, Brando Arriaga, Qiongyu Hao, Wei Cao, Zhaoxia Gao, Jay Vadgama, and Yong Wu. The role of ppm1d in cancer and advances in studies of its inhibitors. Biomedicine &amp; Pharmacotherapy, 125:109956, May 2020. URL: http://dx.doi.org/10.1016/j.biopha.2020.109956, doi:10.1016/j.biopha.2020.109956. This article has 31 citations.](https://doi.org/10.1016/j.biopha.2020.109956)

[7. (Kamada2020Metaldependent) Rui Kamada, Fuki Kudoh, Shogo Ito, Itsumi Tani, Jose Isagani B. Janairo, James G. Omichinski, and Kazuyasu Sakaguchi. Metal-dependent ser/thr protein phosphatase ppm family: evolution, structures, diseases and inhibitors. Pharmacology &amp; Therapeutics, 215:107622, November 2020. URL: http://dx.doi.org/10.1016/j.pharmthera.2020.107622, doi:10.1016/j.pharmthera.2020.107622. This article has 65 citations.](https://doi.org/10.1016/j.pharmthera.2020.107622)

[8. (Jansen2017De) Sandra Jansen, Sinje Geuer, Rolph Pfundt, Rachel Brough, Priyanka Ghongane, Johanna C. Herkert, Elysa J. Marco, Marjolein H. Willemsen, Tjitske Kleefstra, Mark Hannibal, Joseph T. Shieh, Sally Ann Lynch, Frances Flinter, David R. FitzPatrick, Alice Gardham, Birgitta Bernhard, Nicola Ragge, Ruth Newbury-Ecob, Raphael Bernier, Malin Kvarnung, E.A. Helena Magnusson, Marja W. Wessels, Marjon A. van Slegtenhorst, Kristin G. Monaghan, Petra de Vries, Joris A. Veltman, Christopher J. Lord, Lisenka E.L.M. Vissers, and Bert B.A. de Vries. De novo truncating mutations in the last and penultimate exons of ppm1d cause an intellectual disability syndrome. The American Journal of Human Genetics, 100(4):650–658, April 2017. URL: http://dx.doi.org/10.1016/j.ajhg.2017.02.005, doi:10.1016/j.ajhg.2017.02.005. This article has 58 citations.](https://doi.org/10.1016/j.ajhg.2017.02.005)

[9. (Lu2005PPM1D) Xiongbin Lu, Bonnie Nannenga, and Lawrence A. Donehower. Ppm1d dephosphorylates chk1 and p53 and abrogates cell cycle checkpoints. Genes &amp; Development, 19(10):1162–1174, May 2005. URL: http://dx.doi.org/10.1101/gad.1291305, doi:10.1101/gad.1291305. This article has 311 citations.](https://doi.org/10.1101/gad.1291305)

[10. (Douarre2013DNA) Céline Douarre, Xénia Mergui, Assitan Sidibe, Dennis Gomez, Patrizia Alberti, Patrick Mailliet, Chantal Trentesaux, and Jean-François Riou. Dna damage signaling induced by the g-quadruplex ligand 12459 is modulated by ppm1d/wip1 phosphatase. Nucleic Acids Research, 41(6):3588–3599, February 2013. URL: http://dx.doi.org/10.1093/nar/gkt073, doi:10.1093/nar/gkt073. This article has 31 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkt073)

[11. (Burocziova2023Ppm1d) Monika Burocziova, Petr Danek, Anna Oravetzova, Zuzana Chalupova, Meritxell Alberich-Jorda, and Libor Macurek. Ppm1d truncating mutations promote the development of genotoxic stress-induced aml. Leukemia, 37(11):2209–2220, September 2023. URL: http://dx.doi.org/10.1038/s41375-023-02030-8, doi:10.1038/s41375-023-02030-8. This article has 5 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41375-023-02030-8)